3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
4
Withdrawn
1
Unknown
1
Terminated
1
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
11
Urinary Bladder Neoplasms
10
Pancreatic Neoplasms
7
Carcinoma, Merkel Cell
6
Triple Negative Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Ovarian Neoplasms
4
Carcinoma, Transitional Cell
4
Carcinoma, Renal Cell
4
Recurrence
3
Neoplasms
3
Neoplasm Metastasis
3
Colorectal Neoplasms
3
Breast Neoplasms
3
Stomach Neoplasms
2
Lymphoma
2
Lung Neoplasms
2
Leukemia, Myeloid, Acute
2
Carcinoma, Squamous Cell
2
Carcinoma, Hepatocellular
2
Uterine Cervical Neoplasms
1
Turcot syndrome
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Cancer Resectable
1
Non-Muscle Invasive Bladder Neoplasms
1
Nasopharyngeal Neoplasms
1
Multiple Myeloma
1
Microsatellite Instability
1
Interventions
pembrolizumab
51
Ipilimumab
50
Cyclophosphamide
43
Nivolumab
41
aldesleukin
30
Interleukin-2
23
Vemurafenib
20
fludarabine
19
Temozolomide
18
fludarabine phosphate
15
dabrafenib
15
trametinib
12
spartalizumab
10
Radiotherapy
10
Radiosurgery
10
Dacarbazine
10
CTLA-4 Antigen
10
cobimetinib
9
binimetinib
9
poly ICLC
7
encorafenib
7
Paclitaxel
7
atezolizumab
6
Introns
6
Biopsy
6
montanide ISA 51
5
Carboplatin
5
epacadostat
4
MART-1 Antigen
4
Interferon alpha-2
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Melanoma
×
avelumab
×
Clear all
NCT02554812
2024-07-30
JAVELIN Medley
Pfizer
Phase 1/2
Terminated
409 enrolled
108 charts